文献速递头颈与中枢神经肿瘤

血管紧张素II受体阻滞剂、类固醇与放疗治疗胶质母细胞瘤:一项随机多中心试验(ASTER试验)——ANOCEF研究

Angiotensin II receptor blockers, steroids and radiotherapy in glioblastoma-a randomised multicentre trial (ASTER trial). An ANOCEF study.
PubMed 文献 · Eur J Cancer · 2019-02-01

ASTER试验为随机、安慰剂对照、多中心研究,纳入活检或部分切除后组织学确诊的胶质母细胞瘤患者75例,随机接受氯沙坦(37例)或安慰剂(38例)联合标准治疗(放疗+替莫唑胺)。主要目标为比较放疗最后一天控制脑水肿所需类固醇剂量,两组无差异;放疗结束1个月后类固醇剂量、不良事件发生率及中位总生存亦相似。结论:氯沙坦虽耐受良好,但不能减少新诊断胶质母细胞瘤患者同步放化疗期间的类固醇需求。

要点

  • 氯沙坦联合标准治疗未减少放疗最后一天控制脑水肿所需类固醇剂量。
  • 放疗结束1个月后类固醇剂量两组无差异,不良事件发生率相似。
  • 两组中位总生存相似,氯沙坦耐受良好但未改善类固醇需求。

核心结论

  • 氯沙坦虽耐受良好,但不能减少新诊断胶质母细胞瘤患者接受同步放疗和替莫唑胺期间的类固醇需求。

研究设计与样本

  • 随机、安慰剂对照、多中心试验(ASTER试验,ANOCEF研究),纳入活检或部分手术切除后组织学确诊的胶质母细胞瘤患者75例,随机接受氯沙坦(37例)或安慰剂(38例)联合标准治疗(放疗和替莫唑胺)。

主要发现

  • 放疗最后一天控制脑水肿所需类固醇剂量两组无差异。
  • 放疗结束后1个月类固醇剂量两组无差异。
  • 不良事件发生率两组相似。
  • 中位总生存两组相似。

关键数值与推荐

  • 主要终点为放疗最后一天控制脑水肿所需类固醇剂量,两组无差异。
  • 次要终点包括放疗结束后1个月类固醇剂量、磁共振成像评估脑水肿、耐受性和生存,类固醇剂量、不良事件发生率及中位总生存两组均相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glioblastomas (GBMs) induce a peritumoural vasogenic oedema impairing functional status and quality of life. Steroids reduce brain tumour-related oedema but are associated with numerous side-effects. It was reported in a retrospective series that angiotensin receptor blockers might be associated with reduced peritumoural oedema. The ASTER study is a randomised, placebo-controlled trial to assess whether or not the addition of Losartan to standard of care (SOC) can reduce steroid requirement during radiotherapy (RT) in patients with newly diagnosed GBM. PATIENTS AND METHODS: Patients with a histologically confirmed GBM after biopsy or partial surgical resection were randomised between Losartan or placebo in addition to SOC with RT and temozolomide (TMZ). The primary objective was to investigate the steroid dosage required to control brain oedema on the last day of RT in each arm. The secondary outcomes were steroids dosage 1 month after the end of RT, assessment of cerebral oedema on magnetic resonance imaging, tolerance and survival. RESULTS: Seventy-five patients were randomly assigned to receive Losartan (37 patients) or placebo (38 patients). No difference in the steroid dosage required to control brain oedema on the last day of RT, or one month after completion of RT, was seen between both arms. The incidence of adverse events was similar in both arms. Median overall survival was similar in both arms. CONCLUSIONS: Losartan, although well tolerated, does not reduce the steroid requirement in newly diagnosed GBM patients treated with concomitant RT and TMZ. Trial registration number NCT01805453 with ClinicalTrials.gov.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Ursu R, Thomas L, Psimaras D, et al. Angiotensin II receptor blockers, steroids and radiotherapy in glioblastoma-a randomised multicentre trial (ASTER trial). An ANOCEF study. Eur J Cancer. 2019. PMID: 30716716. doi:10.1016/j.ejca.2018.12.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。